Nurix Therapeutics, Inc. – NASDAQ:NRIX

Nurix Therapeutics stock price today

$9.89
-9.21
-48.25%
Financial Health
0
1
2
3
4
5
6
7
8
9

Nurix Therapeutics stock price monthly change

-19.77%
month

Nurix Therapeutics stock price quarterly change

-19.77%
quarter

Nurix Therapeutics stock price yearly change

+96.00%
year

Nurix Therapeutics key metrics

Market Cap
1.40B
Enterprise value
397.11M
P/E
-2.35
EV/Sales
10.28
EV/EBITDA
-2.35
Price/Sales
11.64
Price/Book
1.48
PEG ratio
0.05
EPS
-2.92
Revenue
62.30M
EBITDA
-163.98M
Income
-165.00M
Revenue Q/Q
-60.58%
Revenue Y/Y
2.24%
Profit margin
-466.93%
Oper. margin
-476.01%
Gross margin
0%
EBIT margin
-476.01%
EBITDA margin
-263.21%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Nurix Therapeutics stock price history

Nurix Therapeutics stock forecast

Nurix Therapeutics financial statements

Average Price Target
Last Year

$32.78

Potential upside: 231.42%

Based on estimate of 8 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Nurix Therapeutics, Inc. (NASDAQ:NRIX): Profit margin
Aug 2023 18.46M -36.98M -200.26%
Nov 2023 15.15M -41.95M -276.77%
Feb 2024 16.58M -41.51M -250.33%
May 2024 12.09M -44.54M -368.39%
Nurix Therapeutics, Inc. (NASDAQ:NRIX): Debt to assets
Aug 2023 308195000 74.37M 24.13%
Nov 2023 364539000 164.04M 45%
Feb 2024 312674000 143.92M 46.03%
May 2024 511031000 140.33M 27.46%
Nurix Therapeutics, Inc. (NASDAQ:NRIX): Cash Flow
Aug 2023 -41.13M 22.77M 1.70M
Nov 2023 21.74M -14.37M 4.94M
Feb 2024 -41.95M 35.51M 1.62M
May 2024 -39.70M -131.07M 237.75M

Nurix Therapeutics alternative data

Nurix Therapeutics, Inc. (NASDAQ:NRIX): Employee count
Aug 2023 297
Sep 2023 297
Oct 2023 297
Nov 2023 297
Dec 2023 297
Jan 2024 297
Feb 2024 297
Mar 2024 284
Apr 2024 284
May 2024 284
Jun 2024 284
Jul 2024 284

Nurix Therapeutics other data

31.45% -56.35%
of NRIX is owned by hedge funds
16.98M -25.68M
shares is hold by hedge funds

Nurix Therapeutics, Inc. (NASDAQ:NRIX): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 5765
Feb 2024 0 6812
Apr 2024 0 4907
May 2024 0 3499
Jun 2024 0 25760
Jul 2024 0 14578
Aug 2024 0 39107
Sep 2024 0 9050
Oct 2024 0 19037
Nov 2024 0 12596
Dec 2024 0 5760
Transaction Date Insider Security Shares Price per share Total value Source
Option
RING CHRISTINE officer: Chief Le.. Employee Stock Option (right to buy) 5,760 $1.86 $10,714
Option
RING CHRISTINE officer: Chief Le.. Common Stock 5,760 $1.86 $10,714
Sale
RING CHRISTINE officer: Chief Le.. Common Stock 5,760 $21.73 $125,153
Option
RING CHRISTINE officer: Chief Le.. Employee Stock Option (right to buy) 3,290 $9.57 $31,485
Option
RING CHRISTINE officer: Chief Le.. Common Stock 3,290 $9.57 $31,485
Sale
RING CHRISTINE officer: Chief Le.. Common Stock 3,290 $25 $82,250
Option
RING CHRISTINE officer: Chief Le.. Employee Stock Option (right to buy) 5,760 $1.86 $10,714
Option
RING CHRISTINE officer: Chief Le.. Common Stock 5,760 $1.86 $10,714
Sale
RING CHRISTINE officer: Chief Le.. Common Stock 5,760 $24.28 $139,864
Sale
VAN HOUTE HANS officer: Chief Financial Officer
Common Stock 3,546 $24.28 $86,083
Patent
Application
Filling date: 4 Feb 2020 Issue date: 12 May 2022
Application
Filling date: 5 May 2021 Issue date: 18 Nov 2021
Application
Filling date: 3 Dec 2020 Issue date: 1 Jul 2021
Application
Filling date: 23 Sep 2020 Issue date: 25 Mar 2021
Application
Filling date: 23 Sep 2020 Issue date: 25 Mar 2021
Application
Filling date: 26 Jun 2020 Issue date: 25 Feb 2021
Application
Filling date: 15 May 2020 Issue date: 25 Feb 2021
Application
Filling date: 9 Apr 2020 Issue date: 15 Oct 2020
Monday, 9 December 2024
globenewswire.com
Monday, 2 December 2024
globenewswire.com
Monday, 25 November 2024
globenewswire.com
Wednesday, 20 November 2024
globenewswire.com
Sunday, 17 November 2024
globenewswire.com
Thursday, 31 October 2024
globenewswire.com
Monday, 21 October 2024
globenewswire.com
Saturday, 19 October 2024
globenewswire.com
Wednesday, 16 October 2024
globenewswire.com
Friday, 11 October 2024
zacks.com
globenewswire.com
Wednesday, 9 October 2024
globenewswire.com
Tuesday, 8 October 2024
seekingalpha.com
Monday, 30 September 2024
globenewswire.com
Friday, 6 September 2024
globenewswire.com
Wednesday, 4 September 2024
seekingalpha.com
Thursday, 29 August 2024
globenewswire.com
Thursday, 25 July 2024
zacks.com
Tuesday, 16 July 2024
zacks.com
Thursday, 11 July 2024
zacks.com
globenewswire.com
Wednesday, 19 June 2024
zacks.com
Tuesday, 28 May 2024
globenewswire.com
Monday, 20 May 2024
globenewswire.com
zacks.com
Tuesday, 14 May 2024
globenewswire.com
Tuesday, 7 May 2024
globenewswire.com
Tuesday, 16 April 2024
globenewswire.com
Thursday, 11 April 2024
globenewswire.com
globenewswire.com
  • What's the price of Nurix Therapeutics stock today?

    One share of Nurix Therapeutics stock can currently be purchased for approximately $9.89.

  • When is Nurix Therapeutics's next earnings date?

    Unfortunately, Nurix Therapeutics's (NRIX) next earnings date is currently unknown.

  • Does Nurix Therapeutics pay dividends?

    No, Nurix Therapeutics does not pay dividends.

  • How much money does Nurix Therapeutics make?

    Nurix Therapeutics has a market capitalization of 1.40B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 99.31% to 76.99M US dollars.

  • What is Nurix Therapeutics's stock symbol?

    Nurix Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "NRIX".

  • What is Nurix Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Nurix Therapeutics?

    Shares of Nurix Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Nurix Therapeutics's key executives?

    Nurix Therapeutics's management team includes the following people:

    • Dr. Arthur T. Sands Chief Executive Officer, Pres & Director(age: 63, pay: $852,770)
    • Dr. Gwenn M. Hansen Ph.D. Chief Scientific Officer(age: 54, pay: $673,850)
    • Dr. Christine Ring Gen. Counsel & Sec.(age: 60, pay: $548,450)
  • How many employees does Nurix Therapeutics have?

    As Jul 2024, Nurix Therapeutics employs 284 workers.

  • When Nurix Therapeutics went public?

    Nurix Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 24 Jul 2020.

  • What is Nurix Therapeutics's official website?

    The official website for Nurix Therapeutics is nurixtx.com.

  • Where are Nurix Therapeutics's headquarters?

    Nurix Therapeutics is headquartered at 1700 Owens Street, San Francisco, CA.

  • How can i contact Nurix Therapeutics?

    Nurix Therapeutics's mailing address is 1700 Owens Street, San Francisco, CA and company can be reached via phone at +41 56605320.

  • What is Nurix Therapeutics stock forecast & price target?

    Based on 8 Wall Street analysts` predicted price targets for Nurix Therapeutics in the last 12 months, the avarage price target is $32.78. The average price target represents a 231.42% change from the last price of $9.89.

Nurix Therapeutics company profile:

Nurix Therapeutics, Inc.

nurixtx.com
Exchange:

NASDAQ

Full time employees:

284

Industry:

Biotechnology

Sector:

Healthcare

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

1700 Owens Street
San Francisco, CA 94158

CIK: 0001549595
ISIN: US67080M1036
CUSIP: 67080M103